moneyheap
IMVT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Immunovant, Inc. Common Stock (IMVT) stock moving?
IMVT-1402 met its primary endpoint in a difficult-to-treat rheumatoid arthritis study at the 600mg dose, but the 300mg dose showed no difference from placebo, so the dose response is mixed and the readout is not yet a registrational result. Management plans FDA discussions on a registrational path. Fiscal Q2 2026 EPS of $(0.47) beat the $(0.71) estimate reported by Benzinga. Analysts responded: Wells Fargo kept Overweight and raised its target to $47, while Truist kept Hold and raised its target from $30 to $33. On the same day the company filed a mixed shelf prospectus with undisclosed terms, which signals possible equity issuance and dilution risk. The stock jumped 15.1% on Nov 9, from $30.53 to $35.15, on 3.98M shares, roughly 3x the 30-day average of about 1.2M. It held near highs on Nov 10 with a close of $35.71, a VWAP of $35.63 and 1.64M shares traded. The stock now trades above Truist's new $33 target, so further upside depends on the regulatory path and on how any offering is priced.
News behind the analysis
- Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis StudyImmunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.
- Immunovant's IMVT-1402 600mg Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Trial; 300mg Dose Shows No Difference From PlaceboThe 600mg dose of IMVT-1402 met the primary endpoint in rheumatoid arthritis, while the 300mg dose showed no difference from placebo.
- Immunovant Reports Fiscal Second Quarter 2026 Financial ResultsImmunovant reported a loss of $0.47 per share for the quarter ended September 30, 2026.
- Immunovant Q2 EPS $(0.47) Beats $(0.71) EstimateImmunovant's fiscal Q2 loss per share of $(0.47) came in better than the $(0.71) analyst estimate.
- Immunovant Files Prospectus For Offering Mixed Shelf; Terms UndisclosedImmunovant filed a mixed shelf prospectus for a potential offering, with terms not yet disclosed.
- Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47Wells Fargo kept its Overweight rating and raised its price target on Immunovant to $47.
- Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33Truist Securities kept its Hold rating and raised its price target on Immunovant from $30 to $33.
- Truist Securities Adjusts Immunovant Price TargetTruist Securities raised its Immunovant price target from $30.00 to $33.00 while maintaining a Hold rating.
About Immunovant, Inc. Common Stock
Immunovant is a clinical-stage biotech based in Durham, North Carolina, that develops antibody treatments for autoimmune diseases; Roivant Sciences is its majority owner. Its whole focus is now IMVT-1402, an under-the-skin anti-FcRn antibody. The company dropped its earlier drug, batoclimab, after it failed Phase 3 trials in thyroid eye disease.
How it makes money
Immunovant has no approved products and essentially no revenue from sales. It pays for its research with cash raised from investors, about $800 million as of mid-2026, and reported a net loss of roughly $500 million for the fiscal year ended March 2026. Any future income would come from selling IMVT-1402 if it is approved. Trials that could support approval are under way in Graves' disease, myasthenia gravis, CIDP and Sjögren's disease.
What usually moves IMVT
- IMVT-1402 clinical trial readouts (Graves' disease and myasthenia gravis data expected 2027)
- Competition among FcRn drugs from argenx, J&J and UCB
- Cash burn and possible share sales to raise money
- FDA regulatory decisions
- Moves in the biotech sector and interest rates
Similar companies
In the Daily Standout
- November 9, 2026: on the shortlist +15.69%